Investors

Products
CONCERTAI REGULATORY & RESEARCH

Solutions
Regulatory

External Control Arms Regulatory-grade evidence from RWD

Comparative Cohort Matched group outcome comparison

Feasibility Assessment Trial readiness and alignment

Research

Precision Explorer Insights from real-world data

Patient360 Longitudinal, linked, real-world data

Translational360 Clinico-genomic insights for research

Precision360 Precision insights for oncology
CONCERTAI PRECISION SUITE

Solutions
Precision Suite

Precision Explorer Insights from real-world data

Precision Trials Smarter, faster trial design

Precision GTM Drive engagement and access

Precision360 Precision insights for oncology
CONCERTAI COMMERCIAL SOLUTIONS

Solutions
Commercial Solutions

Precision GTM Drive engagement and access

Accelerated Clinical Outcomes Suite Personalized support, better adherence

STAR Automated therapy access

Specialty Data Aggregation Unified specialty data insights
CONCERTAI CLINICAL DEVELOPMENT

Solutions
Clinical Development

Precision Trials Smarter, Faster Trial Design

Digital Trial Solutions AI-powered, end-to-end trial enablement

CTO-H Design smarter, faster hematological-focused trials

Patient Matching & Automation Site workflows for trial matching

Accelerated Clinical Trials (Coming Soon) Streamlined full-trial lifecycle support
CONCERTAI CANCERLINQ

Solutions
SmartLinQ

Clinical Quality & Care Gaps Monitor, measure, improve outcomes

TriaLinQ AI-powered trial screening

RxLinQ Molecular-driven therapy selection

PatientLinQ Real-time clinical guidance
CONCERTAI TERARECON

Solutions
TeraRecon
(You will be redirected to TeraRecon's Homepage)

Advanced Visualization (Intuition) High-performance clinical visualization

Artificial Intelligence (Eureka) AI insights for imaging

Therapeutic Areas Tailored imaging by specialty

Premier Success Expert support, maximized value
CARAai
Resources
- Publications
- Newsroom
- Content
- Events
Company

ConcertAI is Backed by Investors Committed to Innovation in Life Sciences and Healthcare

Our investors are committed to our continued growth and innovation in RWD and technology products and services for regulatory and non-regulatory applications, expansion into adjacent therapy areas, and commercial patient solutions.

SAI Group

SAI Group is the fastest-growing private group of B2B AI companies, backed by a $1 billion commitment to deliver next-generation AI solutions for transforming the enterprise. Since its founding in 2017, SAI Group has grown rapidly to a group of six companies with a combined revenue run rate approaching $300 million. Over 1,600 talented leaders, data scientists, and other professionals operate the group under the leadership of Dr. Romesh Wadhwani, one of Silicon Valley’s most successful serial entrepreneurs.

Learn More

Dr. Romesh Wadhwani

Founder, Chairman and CEO, SymphonyAI Group

"ConcertAI is delivering significant customer value today and is poised to drive substantial AI innovation in healthcare and life sciences."

Sixth Street

Sixth Street is a leading global investment firm with over $60 billion in assets under management and committed capital. Sixth Street uses its long-term, flexible capital, data-enabled capabilities, and One Team culture to develop themes and offers solutions to companies across all stages of growth. Sixth Street’s Healthcare and Life Sciences team provides strategic capital and forms long-term partnerships with companies creating new technologies to address pressing healthcare challenges and improve patient care. Select Sixth Street investments include Biohaven, Caris Life Sciences, Datavant, DrFirst, Mammoth Biosciences, MDLIVE, and VisiQuate.

Learn More

Andrew Goldfarb

Partner, Declaration Partners

"We are impressed with ConcertAI's innovative culture, technology and leadership. ConcertAI is positioned to empower next generation clinical research, accelerate breakthrough therapies and improve patient outcomes."

Declaration Partners

Declaration Partners is the investment firm backed by the family office of David M. Rubenstein, the Co-Founder of The Carlyle Group. Declaration Partners makes direct private equity and real estate investments, including building platform businesses, providing growth equity capital, seeding early stage private funds and venture studios, and partnering with family-owned businesses.

Maverick Ventures

Maverick Ventures is the venture arm of Maverick Capital, an investment firm managing more than $10 billion. Combining the resources of a global firm with the benefits of an agile, focused team, Maverick Ventures supports entrepreneurs through an evergreen structure from seed through maturity. With over 25 years of early-stage investment experience, the Maverick Ventures team has funded more than 80 companies in the healthcare, software and deep technology sectors.

Alliance Bernstein PCI

AB Private Credit Investors is the middle market direct lending platform of AllianceBernstein L.P (AB). AB-PCI manages approximately $9.2 billion in capital available for investment and offers a range of financing solutions to middle market companies, including having the capacity to invest up to $150 million of credit to a single borrower while also making sizeable growth equity investments.

The investment in ConcertAI was executed as part of AB-PCI’s Growth Stage Capital initiative (AB-GSC). AB-GSC caters to high growth technology companies backed by leading venture capital and growth equity firms. Other recent AB-GSC investments include companies such as Rubrik, Workfront, Degreed, Fuze and DataRobot.

(You will be redirected to TeraRecon's Homepage)

Investors

ConcertAI is Backed by Investors Committed to Innovation in Life Sciences and Healthcare

SAI Group

Dr. Romesh Wadhwani

Sixth Street

Andrew Goldfarb

Declaration Partners

Maverick Ventures

Alliance Bernstein PCI

Products

CARAai

Resources

Company

Support